(Q33345782)

26 July 2017

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia (English)

1 reference

26 July 2017

0 references

1 reference

prolymphocytic leukemia

1 reference

inferred from title

author

Francesco Di Raimondo

object named as

Francesco Di Raimondo

series ordinal

4

0 references

Alessandra Ferrajoli

series ordinal

6

object named as

Alessandra Ferrajoli

1 reference

26 July 2017

3

Susan O'Brien

1 reference

26 July 2017

8

Michael J Keating

1 reference

26 July 2017

5

Susan Lerner

1 reference

26 July 2017

7

Enrica Morra

1 reference

26 July 2017

1

Marco Montillo

1 reference

26 July 2017

2

Alessandra Tedeschi

1 reference

PubMed ID

12491512

26 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

26 July 2017

1 reference

26 July 2017

97

1 reference

26 July 2017

114-120

1 reference

26 July 2017

1

1 reference

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine therapy in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11000

7 January 2021

Identifiers

DOI

10.1002/CNCR.11000

1 reference

26 July 2017

1 reference

PubMed ID

12491512